Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/american-medical-association/age-dependent-neutralization-of-sars-cov-2-and-p-1-variant-by-vaccine-A9rAnNidpv
References (6)
-
Polack (2020)
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.N Engl J Med, 383
-
Haas (2021)
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.Lancet, 397
-
Baden (2021)
Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.N Engl J Med, 384
-
COVID-19 vaccine breakthrough infections reported to CDC—United States, January 1-April 30, 2021.
MMWR Morb Mortal Wkly Rep, 70
-
Khoury (2021)
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.Nat Med
-
Kontopantelis (2021)
Excess mortality in England and Wales during the first wave of the COVID-19 pandemic.J Epidemiol Community Health, 75
- Publisher
- American Medical Association
- Copyright
- Copyright 2021 American Medical Association. All Rights Reserved.
- ISSN
- 0098-7484
- eISSN
- 1538-3598
- DOI
- 10.1001/jama.2021.11656
- Publisher site
- See Article on Publisher Site
Abstract
This study examines the relationship between age and neutralizing antibody titers against the SARS-CoV-2 USA-WA1/2020 strain and the P.1 variant after 2 doses of the BNT162b2 vaccine.
Journal
JAMA – American Medical Association
Published: Sep 7, 2021